- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00429975
Ceftriaxone Vs Levofloxacin on Cytokine Expression in Pneumococcal Pneumonia
Comparison Between Ceftriaxone and Levofloxacin on Cytokine Expression Over Time in Severe Pneumococcal Pneumonia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Bacterial alveolar invasion is followed by a compartmentalized inflammatory response. Data suggest that some antimicrobials may induce a differential release of cytokines, with the potential of either accelerating or down regulating cytokine production.
The aim of our study was to compare the effects of ceftriaxone compared with levofloxacin on cytokine systemic concentrations in patients with pneumococcal pneumonia.
Study Type
Enrollment
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Barcelona
-
Terrassa, Barcelona, Spain, 08221
- Hospital Mútua de Terrassa
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- patients with an acute febrile respiratory illness accompanied by a new radiographic infiltrate consistent with this diagnosis.
- and with a confirmed pneumococcal aetiology
Exclusion Criteria:
- age < 18 years,
- pneumonia distal to endobronchial obstruction,
- pulmonary tuberculosis,
- bronchiectasis,
- known allergy to B-lactams or fluoroquinolones,
- underlying systemic autoimmune disease
- immunocompromised states including patients on maintenance oral corticosteroids, HIV infection,
- pregnancy,
- patients that received antimicrobial therapy in the 15 days preceding the current episode and those who had received fluoroquinolones in the last month, or non steroidal anti-inflammatory therapy in the last two weeks.
- Patients with renal failure (serum creatinine > 2 mg / dL),
- and patients with a documented pneumococcal pneumonia in the previous 4 weeks
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
|---|
|
Circulating levels of pro and anti-inflammatory cytokines at 0h, 24, 72 h and 120 h from inclusion
|
Secondary Outcome Measures
Outcome Measure |
|---|
|
the relationship between cytokine expression, clinical variables and severity of disease.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: ESTHER CALBO, MD, Hospital Mútua de Terrassa
- Principal Investigator: MONTSERRAT ALSINA, MD, Hospital Mutua Terrassa
- Principal Investigator: MARIONA XERCAVINS, MD, Hospital Mútua de Terrassa
- Principal Investigator: EVA CUCHI, MD, Hospital Mútua de Terrassa
- Principal Investigator: MONICA RODRIGUEZ-CARBALLEIRA, PhD, Hospital Mútua de Terrassa
- Study Director: JAVIER GARAU, PhD, Hospital Mútua de Terrassa
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Lung Diseases
- Bacterial Infections
- Bacterial Infections and Mycoses
- Streptococcal Infections
- Gram-Positive Bacterial Infections
- Pneumonia, Bacterial
- Pneumococcal Infections
- Pneumonia
- Pneumonia, Pneumococcal
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antineoplastic Agents
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Anti-Bacterial Agents
- Cytochrome P-450 Enzyme Inhibitors
- Cytochrome P-450 CYP1A2 Inhibitors
- Anti-Infective Agents, Urinary
- Renal Agents
- Ceftriaxone
- Levofloxacin
- Ofloxacin
Other Study ID Numbers
- FIS G03/103
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.